DVAX — Dynavax Technologies Share News
0.000.00%
Last trade - 00:00- $1.76bn
- $1.38bn
- $277.25m
Brief: Dynavax Technologies Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Dynavax Technologies Corp reports results for the quarter ended in June - Earnings Summary
Brief: Dynavax Technologies Q2 Net Income USD 3.431 Million
Dynavax Technologies Corp expected to post a loss of 9 cents a share - Earnings Preview
Dynavax Technologies Corp reports results for the quarter ended in March - Earnings Summary
Brief: Dynavax Reports First Quarter 2023 Financial Results
Brief: Dynavax Technologies Q1 product revenues USD 43.451 million
Dynavax Technologies Corp expected to post a loss of 13 cents a share - Earnings Preview
Brief: Dynavax Announces Great Britain Marketing Authorization For Heplisav B, A Two-Dose Adult Hepatitis B Adjuvanted Vaccine
Brief: Dynavax Reports Fourth Quarter And Full Year 2022 Financial Results
Dynavax Technologies Corp reports results for the quarter ended in December - Earnings Summary
Dynavax Technologies Corp expected to post earnings of 43 cents a share - Earnings Preview
Brief: Dynavax Announces Uplisting To The Nasdaq Global Select Market
Dynavax Technologies Corp reports results for the quarter ended in September - Earnings Summary
Dynavax Technologies Corp expected to post earnings of 33cents a share - Earnings Preview
Brief: Dynavax Announces First Participant Dosed In Phase 2 Clinical Trial Evaluating Adjuvanted Plague Vaccine
Brief: Clover Announces Positive Phase 2/3 Results In Adolescents For COVID-19 Vaccine
Brief: Dynavax Technologies Corp - Q2 Revenue Of $256.5 Mln, Up 386%
Dynavax, Alpha & Omega Semiconductor jump on S&P SmallCap inclusion